Open AccessRisk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
Author(s) -
Darya Kizub,
Jieling Miao,
Mark M. Schubert,
Alexander Paterson,
Mark Clemons,
Elizabeth Claire Dees,
James N. Ingle,
Carla Falkson,
William E. Barlow,
Gabriel N. Hortobágyi,
Julie R. Gralow
Publication year - 2020
Publication title -
supportive care in cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.133
H-Index - 112
eISSN - 1433-7339
pISSN - 0941-4355
DOI - 10.1007/s00520-020-05748-8
Subject(s) - medicine , bisphosphonate , breast cancer , bisphosphonate associated osteonecrosis of the jaw , periodontitis , zoledronic acid , osteonecrosis of the jaw , cancer , oncology , dentistry , osteoporosis
Bisphosphonates reduce bone metastases in postmenopausal women with early-stage breast cancer but carry the risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). We describe risk factors for BRONJ and compare BRONJ provoked by infection or trauma with spontaneous lesions, which carry a better prognosis.